CD24Fc Ameliorates Immune-related Adverse Events While Preserving Anti-tumor Therapeutic Effect

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2022 Jul 14

PMID 35835736

Authors

Mingyue Liu

Xu Wang

Xuexiang Du

Yan Zhang

Chunxia Ai

Siwen Hu-Lieskovan

Tianhong Li

Martin Devenport

Yang Liu

Pan Zheng

Affiliations

Soon will be listed here.

Citing Articles

Multiple functions of HMGB1 in cancer.

Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B Front Oncol. 2024; 14:1384109.

PMID: 38725632 PMC: 11079206. DOI: 10.3389/fonc.2024.1384109.

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.

Magenau J, Jaglowski S, Uberti J, Farag S, Riwes M, Pawarode A Blood. 2023; 143(1):21-31.

PMID: 37647633 PMC: 10934299. DOI: 10.1182/blood.2023020250.

Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events.

Cina M, Venegas J, Young A Immunol Rev. 2023; 318(1):110-137.

PMID: 37565407 PMC: 10529261. DOI: 10.1111/imr.13250.

The biological roles of CD24 in ovarian cancer: old story, but new tales.

Gu Y, Zhou G, Tang X, Shen F, Ding J, Hua K Front Immunol. 2023; 14:1183285.

PMID: 37359556 PMC: 10288981. DOI: 10.3389/fimmu.2023.1183285.

CD24-Siglec interactions in inflammatory diseases.

Liu Y, Zheng P Front Immunol. 2023; 14:1174789.

PMID: 37228622 PMC: 10203428. DOI: 10.3389/fimmu.2023.1174789.

References

Welker J, Pulido J, Catanzaro A, Malvestutto C, Li Z, Cohen J . Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Infect Dis. 2022; 22(5):611-621. PMC: 8916779. DOI: 10.1016/S1473-3099(22)00058-5. View

Baskin G, Murphey-Corb M, Martin L, SOIKE K, Hu F, Kuebler D . Lentivirus-induced pulmonary lesions in rhesus monkeys (Macaca mulatta) infected with simian immunodeficiency virus. Vet Pathol. 1991; 28(6):506-13. DOI: 10.1177/030098589102800607. View

Barkal A, Brewer R, Markovic M, Kowarsky M, Barkal S, Zaro B . CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572(7769):392-396. PMC: 6697206. DOI: 10.1038/s41586-019-1456-0. View

Song N, Allen C, Vilgelm A, Riesenberg B, Weller K, Reynolds K . Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. J Hematol Oncol. 2022; 15(1):5. PMC: 8744064. DOI: 10.1186/s13045-021-01222-y. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View